Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1Phase 1 1

Status

Recruiting 5Unknown 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 1789Neoplasms 1516Carcinoma, Non-Small-Cell Lung 1053Prostatic Neoplasms 965Colorectal Neoplasms 889Lung Neoplasms 809Pancreatic Neoplasms 583Carcinoma, Hepatocellular 543Leukemia, Myeloid, Acute 540Stomach Neoplasms 523Ovarian Neoplasms 513Neoplasm Metastasis 492Multiple Myeloma 491Recurrence 417Melanoma 390Squamous Cell Carcinoma of Head and Neck 374Uterine Cervical Neoplasms 366Brain Neoplasms 364Head and Neck Neoplasms 355Esophageal Neoplasms 320Precursor Cell Lymphoblastic Leukemia-Lymphoma 313Endometrial Neoplasms 311Lymphoma 309Triple Negative Breast Neoplasms 301Glioblastoma 298Rectal Neoplasms 284Urinary Bladder Neoplasms 268Sarcoma 266Hematologic Neoplasms 266Colonic Neoplasms 257

Interventions

nimotuzumab 1lenvatinib 1atezolizumab 1Tirapazamine 1Sorafenib 1Radiotherapy 1Radiosurgery 1Immune Checkpoint Inhibitors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × HCC × Clear all
NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting
40 enrolled

HCC

NCT06844357 2025-04-06

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Zhejiang Raygene Pharmaceuticals Co., Ltd

Phase 2/3 Recruiting
300 enrolled

HCC

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

Chinese University of Hong Kong

Phase 2 Recruiting
44 enrolled

HCC

NCT06463444 2024-06-17

Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

Tongji Hospital

Phase 1 Recruiting
30 enrolled

HCC

NCT06413017 2024-05-14

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
30 enrolled

HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡